Precipio announced it received an order for the launch of their RUO ICE COLD-PCR (ICP) Liquid Biopsy technology in Singapore by Clearbridge Health.
Precipio (NASDAQ:PRPO) announced it received an order for the launch of their RUO ICE COLD-PCR (ICP) Liquid Biopsy technology in Singapore by Clearbridge Health.
As quoted in the press release:
CBH has placed an initial order of ICP kits to be delivered during Q4 of 2017 and Q1 2018. The Company also announced that CBH intends to launch Precipio’s Pathology services, as well as its SmartPath™ Second Opinion service. SmartPath™ connects the patient and their treating physician with experts within Precipio’s academic network to ensure accurate diagnoses. Precipio recently conducted comprehensive training at CBH headquarters in Singapore with the CBH sales team representatives covering Singapore, China, Hong Kong, India, Philippines, Malaysia and Indonesia.
“We are very excited about ICE COLD-PCR™ technology and Smartpath™,” said Jeremy Yee, CEO of Clearbridge Health.